entacingene turiparvovec (AAV-CNGB3) / MeiraGTx - LARVOL DELTA

Long-Term Follow-Up Gene Therapy Study for Achromatopsia CNGB3 and CNGA3 (clinicaltrials.gov) - P=N/A | N=34 | Terminated | Sponsor: MeiraGTx UK II Ltd | Completed ➔ Terminated; Strategic decision to not further develop AAV8-hCARp.hCNGB3 and AAV8-hG1.7p.coCNGA3. The decision is not due to safety concerns.

Trial termination • Achromatopsia • Gene Therapies • Ophthalmology

Long-Term Follow-Up Gene Therapy Study for Achromatopsia CNGB3 and CNGA3 (clinicaltrials.gov) - P1/2 | N=34 | Completed | Sponsor: MeiraGTx UK II Ltd | Active, not recruiting ➔ Completed | Trial completion date: Jan 2026 ➔ Apr 2024 | Trial primary completion date: Jan 2026 ➔ Apr 2024

Gene therapy • Trial completion • Trial completion date • Trial primary completion date • Achromatopsia • Gene Therapies • Ophthalmology

Long-Term Follow-Up Gene Therapy Study for Achromatopsia CNGB3 and CNGA3 (clinicaltrials.gov) - P1/2; N=34; Active, not recruiting; Sponsor: MeiraGTx UK II Ltd; Recruiting ➔ Active, not recruiting; N=72 ➔ 34; Trial completion date: Aug 2024 ➔ Jan 2026; Trial primary completion date: Jul 2024 ➔ Jan 2026

Clinical • Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Achromatopsia • Gene Therapies • Ophthalmology

[VIRTUAL] A002 GENES, ENVIRONMENT, AND TREATMENT: CHARACTERIZING RISK IN ILD (ATS 2021) - No abstract available

"#ATS2021 Mini Symposium A002 Gene, Environment, And Treatment: Characterizing Risk in ILD 5/16/2021 8:00:00 AM - 5/16/2021 9:30:00 AM EDT" (@ATS_EOPH)

Gene Therapy for Achromatopsia (CNGB3) (clinicaltrials.gov) - P1/2; N=23; Completed; Sponsor: MeiraGTx UK II Ltd; Trial primary completion date: May 2019 ➔ Oct 2019

Clinical • Trial primary completion date • Achromatopsia • Ophthalmology

Gene Therapy for Achromatopsia (CNGB3) (clinicaltrials.gov) - P1/2; N=23; Completed; Sponsor: MeiraGTx UK II Ltd; Active, not recruiting ➔ Completed

Clinical • Trial completion